The strong Phase 2 data enhance the probability of success for cretostimogene in high-risk NMIBC, but the stock already reflects significant optimism (95% analyst buy). Watch for durability data later this year and next catalysts from Phase 3 trials (BOND-003, PIVOT-006).
CGON drugs
CGON drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $66.93entry
- T+1 · 6mo ago −5.98%α −5.91% · $62.93
- T+5 · 6mo ago −4.00%α −4.97% · $64.25
- T+20 · 5mo ago −11.01%α −13.13% · $59.56
- T+60 · 3mo ago +15.09%α +10.58% · $77.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CG Oncology announced positive Phase 2 data for cretostimogene + gemcitabine in high-risk NMIBC, showing 89.5% HG-EFS at 6 months and 85.7% CR in CIS patients, with no grade 3+ TRAEs. The data support a potential intravesical combination regimen but remain early and require durability follow-up.
Key Facts
- HG-EFS of 96.0% at 3 months and 89.5% at 6 months in ITT population (median follow-up 6.6 months)
- CR rate of 85.7% in CIS-containing ITT population (95% CI 67.3%-96.0%) and 92.3% in efficacy-evaluable population (95% CI 74.9%-99.1%)
- No grade 3 or greater treatment-related adverse events reported; favorable safety profile
- Data to be presented at AUA 2026; durability data expected later in 2026
Financial Impact
Positive read-through for cretostimogene's commercial potential in NMIBC; no revenue impact yet as product remains investigational
Risk Factors
- Early data with small sample size (28 CIS patients); durability results could disappoint
- Phase 3 trials (BOND-003, PIVOT-006) still ongoing and may not replicate these results
- Competitive landscape includes other intravesical therapies (e.g., retifanlimab, targeted agents)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295777 |
Track record
25 reports on CGON
6 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers